ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา

Size: px
Start display at page:

Download "ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา"

Transcription

1 ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา 1

2 CONTENT Chronic Daily Headache Medical Overused Headache Management

3 Headaches are one of the most common symptoms List of differential diagnoses over 300 different types and causes Cause of most headaches can determined by a careful history and neurologic examination Neurol Clin 1996;14:1-2. 3

4 3026 neuroimaging scans patients with headache and normal neurologic examination is quite low; brain tumors, 0.8% arteriovenous malformations, 0.2% hydrocephalus, 0.3% aneurysm,0.1% subdural hematoma, 0.2% strokes, 1.2% 1440 scans of patients with migraine: brain tumor, 0.3% arteriovenous malformation, 0.07% saccular aneurysm, 0.07% White matter abnormality reported on MRI in all types of migraine, range from 12% to 46% Neurol Clin 1996;14:1-2. 4

5

6 Consider Headache Prophylactic Therapy Patient s condition and related disorder

7 emegal lery.co m

8 CONTENT 1 Chronic Daily Headache

9 headache 15 d/mo, for at least 3 months lasting more than 4 hours CDH has 4 subtypes: Chronic Daily Headache (CDH) Definition: Chronic migraine CDH New daily persistent headache Hemicrania continua Chronic tension type Headache 2011;51 Suppl 2:

10 Chronic Migraine Unilateral or bilateral Pulsating in quality Moderate to severe intensity Worse by routine activity Hemicranial Continua Unilateral Daily and continuous Without pain free period Moderate intensity but sometime severe Indomethacin-response New Daily Persistent Headache New onset (within 3d) Persistent Character of pain not making diagnosis Chronic Tension Type Bilateral location Pressing/tightening (non-pulsating) Mild to moderate intensity Not worsen by routine activity N Engl J Med 2006;354: Cephalgia 2004;24:

11 Chronic Daily Headache (CDH) 15 days a month more than 4 hours a day If it lasts less than 4 hours a day Trigeminal Autonomic Cephalalgia (TAC) TACs include Episodic & Chronic cluster headache Episodic & Chronic paroxysmal hemicrania SUNCT Hypnic headache J Headache Pain 2007;8:

12 12

13 2 Medical Overused Headache CONTENT

14 Regular overuse for 3 months of one or more drugs for acute headache treatment (depending on the medication) 10 d/mo 15 d/mo Duration Ergotamine Paracetamol Triptan NSAIDs 3 months Opioids Combinations The International Classification of Headache Disorders 3rd edition 14

15 In a study on episodic migraine (n=532) 1-year incidence of chronic headache was 14% Higher preponderance in woman higher headache frequency at baseline taking greater amounts of analgesics Poorer quality of life (Measured by scales: higher score on MIDAS: Migraine disability assessment scale) MOH Introduction & Epidemiology

16 Characters of MOH Occur daily or nearly daily Vary in severity, type and location from time to time Low threshold for head pain (physical or mental effort) Withdrawal symptoms occur when stop pain medication (need medications) Improvement of headache occurs after stop medications Prophylactic medications ineffective while taking excess amounts of pain relief drugs

17 MOH is 3 rd most common form of headache (following TTH and migraine) Unclear pathophysiological mechanism All analgesic drugs can inducing MOH Characters of MOH Drug withdrawal is the most effective treatment Early initiate adequate prophylactic treatment regimens

18 Diagnostic Criteria for Medications-overuse Headache (MOH) Headache present 15d per month Regular overuse for 3 months of one or more drugs for acute headache treatment (depending on the medication) Headache develop or markedly worsened during medication overuse Headache resolve or improved from previous pattern within 2 months after stop of overused medication The International Classification of Headache Disorders 3rd edition 18

19 3 Management CONTENT

20 Patients should be advised to Correction for Expectation Maintain a regular lifestyle, with adequate sleep, meals, exercise, and manage stress. Any identifiable Trigger should be avoided Taper overused medication/caffeine over 4-6 wk Add preventive medications Treatment of MOH Out patient

21 Treatment of MOH In patient Abrupt drug withdrawal is the treatment of choice for MOH Fluid replacement Antiemetic Analgesic Prednisolone 60 mg in d1 taper by 20 mg q 2d total 6d Start preventive medications simultaneously

22 Reduce - attack frequency, severity, and duration - acute medication use and prevent MOH - unnecessary medical care Improve - responsiveness to acute attack - QOL GOAL of Preventive treatment

23 Principle of Prophylactic Initiated with first line medications Initiated with lowest effective dose and increased slowly until clinical benefits are achieved without any adverse events Adequate trial 2-3 months should be given to each drug Use of a long-acting formulation may improve compliance Br J Pharmacol 2001;132:

24 Principle of Prophylactic Combination of first line drugs should be tried before advancing to 2 nd line drug (in case of monotherapy are ineffective) Lack of response to several prophylactic drugs remain use of medication overuse should be suspected Gradual withdrawal should be considered after 6 to 12 months of effective prophylaxis, Br J Pharmacol 2001;132:

25 Treatment of MOH Medications Dosage TRICYCLIC ANTIDEPRESSANT Amitriptyline mg/d Nortriptyline mg/d BETA-BLOCKER Propranolol mg/d ANTIEPILEPTICS Topiramate mg/d Valproate mg/d Gabapentin mg/d CALCIUM CHANNEL BLOCKER Flunarizine 5-10 mg/d Verapamil mg/d Am Fam Physician 2006;73:

26 Neurology 2012;78:

27 BOTULINUM TOXIN for Chronic Migraine Totally 155 u

28 Non-pharmacologic Prevention Adequate hydration Adequate sleep Managing stress, anxiety, depression Exercise Behavioral therapy Other relaxation Acupuncture Transcutaneous Electrical Nerve Stimulation (TENS) Br J Pharmacol 2001;132:

29 March 2014, the FDA approved the first device for the preventive treatment of migraine for adults Supraorbital Transcutaneous Stimulator 29

Index. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.

Index. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type. Prim Care Clin Office Pract 31 (2004) 441 447 Index Note: Page numbers of article titles are in boldface type. A Abscess, brain, headache in, 388 Acetaminophen for migraine, 406 407 headache from, 369

More information

Management of headache

Management of headache Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,

More information

Dubai Standards of Care (Migraine)

Dubai Standards of Care (Migraine) Dubai Standards of Care 2018 (Migraine) Preface Migraine is one of the most common problem dealt with in daily practice. In Dubai, the management of migraine is done through various different strategies.

More information

How do we treat migraine? New SIGN Guidelines

How do we treat migraine? New SIGN Guidelines How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood

More information

A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN

A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline Scottish intercollegiate Guidelines Network SIGN November 2008. PETER FRAMPTON MSc MCOptom BAppSc (Optom)(AUS)

More information

COMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS

COMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS ACUTE THEAPIES TIPTANS TICYCLIC ANTIDEPESSANTS When starting acute treatment, healthcare professionals should warn patients about the risk of developing medication-overuse headache. ASPIIN Aspirin (900

More information

Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert

Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert Childhood headache: Is it really difficult to manage? It shouldn t be... But it can be...

More information

Chronic Daily Headaches

Chronic Daily Headaches Chronic Daily Headaches ANWARUL HAQ, MD, MRCP(UK), FAHS DIRECTOR BAYLOR HEADACHE CENTER, DALLAS, TEXAS DISCLOSURES: None OBJECTIVES AT THE CONCLUSION OF THIS ACTIVITY, PARTICIPANTS WILL BE ABLE TO: define

More information

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. In 1962, Bille published landmark epidemiologic survey of headache among 9,000 school

More information

HEADACHE: Benign or Severe Dr Gobinda Chandra Roy

HEADACHE: Benign or Severe Dr Gobinda Chandra Roy HEADACHE: Benign or Severe Dr Gobinda Chandra Roy Associate Professor, Department of Medicine, Shaheed Suhrawardy Medical College and Hospital Outlines 1. Introduction 2. Classification of headache 3.

More information

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau: Chronic Daily Headache Bassel F. Shneker, MD, MBA Associate Professor Vice Chair, OSU Neurology The Ohio State University Wexner Medical Center Financial Disclosures None related to the presentation Grants

More information

Aleksandra Radojičić. Headache Center, Neurology Clinic, Clinical Center of Serbia

Aleksandra Radojičić. Headache Center, Neurology Clinic, Clinical Center of Serbia European Headache School Belgrade 2012 MEDICATION OVERUSE HEADACHE Aleksandra Radojičić Headache Center, Neurology Clinic, Clinical Center of Serbia Historical data First cases were described in XVII century

More information

SIGN on the pharmacological management of migraine

SIGN on the pharmacological management of migraine GUIDELINES SIGN on the pharmacological management of migraine STEVE CHAPLIN In February 2018, the Scottish Intercollegiate Guidelines Network (SIGN) published a new guideline on the pharmacological management

More information

Reflections on NICE Headache Guideline. Dr Kay Kennis GPwSI in Headache, Bradford

Reflections on NICE Headache Guideline. Dr Kay Kennis GPwSI in Headache, Bradford Reflections on NICE Headache Guideline Dr Kay Kennis GPwSI in Headache, Bradford Overview The process of guideline development illustrated with the headache guideline Reflections on the process Key recommendations

More information

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time

More information

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary Chronic Migraine in Primary Care December 11 th, 2017 Werner J. Becker University of Calgary Disclosures Faculty: Werner J. Becker Relationships with commercial interests: Grants/Research Support: Clinical

More information

MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache

MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache Measure Description Percentage of patients age 18 years old and older with a diagnosis of primary headache

More information

Adult with headache. Problem-specific video guides to diagnosing patients and helping them with management and prevention

Adult with headache. Problem-specific video guides to diagnosing patients and helping them with management and prevention Adult with headache Problem-specific video guides to diagnosing patients and helping them with management and prevention London Strategic Clinical Networks London Neuroscience Strategic Clinical Network

More information

Preventive treatment of migraine. Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA

Preventive treatment of migraine. Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA Preventive treatment of migraine Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA No disclosures Disclosures Many preventive treatments for migraine are not FDA-approved

More information

Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE

Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE IHS Classification 1989 (updated 2004) Primary Headaches 4 categories Migraine Tension-type Cluster and other trigeminal

More information

Strategies in Migraine Care

Strategies in Migraine Care Strategies in Migraine Care Julie L. Roth, MD Rhode Island Hospital Assistant Professor, Neurology The Warren Alpert Medical School of Brown University March 28, 2015 Financial Disclosures None. Objectives

More information

FINANCIAL DISCLOSURE. No relevant financial relationships

FINANCIAL DISCLOSURE. No relevant financial relationships Sleep and Headache Paul Mathew, MD, FAHS Director of Continuing Medical Education John R. Graham Headache Center Brigham & Women s Hospital Director of Headache Medicine Cambridge Health Alliance Harvard

More information

Measure Components Numerator Statement

Measure Components Numerator Statement MEASURE #5: OVERUSE OF OPIOID CONTAINING MEDICATIONS FOR PRIMARY HEADACHE DISORDERS Headache For Quality Improvement Only. Not to be used for Public Reporting or Accountability Measure Description Percentage

More information

Managing Headache in Acute Medicine. Ben Lovell Consultant Physician in Acute Medicine University College London Hospital

Managing Headache in Acute Medicine. Ben Lovell Consultant Physician in Acute Medicine University College London Hospital Managing Headache in Acute Medicine Ben Lovell Consultant Physician in Acute Medicine University College London Hospital Some ED headache stats Arrive by ambulance 31% Median age 39 Worst ever headache

More information

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES 1 JUSTIN A. OSSMAN, MD CHATTANOOGA FAMILY MEDICINE UPDATE OH, MY ACHING HEAD! MANAGING HEADACHE IN THE OUTPATIENT SETTING 2 I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE OBJECTIVES International

More information

By Nathan Hall Associate Editor

By Nathan Hall Associate Editor By Nathan Hall Associate Editor 34 Practical Neurology March 2005 These new rules may change the definition of head pain, but some practitioners may find the new guidelines themselves to be a source of

More information

Trigeminal Autonomic Cephalalgias. Disclosures. Objectives 6/20/2018. Rashmi Halker Singh, MD FAHS UCNS Review Course June 2018

Trigeminal Autonomic Cephalalgias. Disclosures. Objectives 6/20/2018. Rashmi Halker Singh, MD FAHS UCNS Review Course June 2018 Trigeminal Autonomic Cephalalgias Rashmi Halker Singh, MD FAHS UCNS Review Course June 2018 Disclosures Honoraria from Allergan and Amgen for advisory board, Current Neurology and Neuroscience Reports

More information

Update on Diagnosis and Management of Migraines

Update on Diagnosis and Management of Migraines Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish

More information

Headaches in Children and Adolescents. Paul Shillito

Headaches in Children and Adolescents. Paul Shillito Headaches in Children and Adolescents Paul Shillito Topics For Discussion What s different about childhood migraine Chronic daily headache (CDH) Tumours and other things to worry about Management of childhood

More information

Management options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM

Management options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Management options for Migraine Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Assessment The Migraine Disability Assessment Score MIDAS Complete loss of work Partial loss of work Off

More information

INTERVIEW WITH F. MICHAEL CUTRER, MD

INTERVIEW WITH F. MICHAEL CUTRER, MD ASIM Mar p107-111 3/18/01 9:19 AM Page 107 INTERVIEW WITH F. MICHAEL CUTRER, MD Dr. Cutrer is Director of the Partners Headache Center at Massachusetts General and Brigham and Women s Hospitals in Boston.

More information

Headache Master School Japan-Osaka 2016 II. Management of refractory headaches Case Presentation 2. SUNCT/SUNA: concept, management and prognosis

Headache Master School Japan-Osaka 2016 II. Management of refractory headaches Case Presentation 2. SUNCT/SUNA: concept, management and prognosis Headache Master School Japan-Osaka 2016 II. Management of refractory headaches Case Presentation 2. SUNCT/SUNA: concept, management and prognosis Noboru Imai(Department of Neurology, Japanese Red Cross

More information

Overuse of barbiturate and opioid containing medications for primary headache disorders Description

Overuse of barbiturate and opioid containing medications for primary headache disorders Description Measure Title Overuse of barbiturate and opioid containing medications for primary headache disorders Description Percentage of s age 12 years and older with a diagnosis of primary headache who were prescribed

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: occipital_nerve_stimulation 8/2010 5/2017 5/2018 5/2017 Description of Procedure or Service Occipital nerve

More information

Migraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital

Migraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital Migraine Management Jane Melling Headache nurse Mater Misericordiae Hospital Migraine facts Among the most common disorders of the nervous system 3 rd most prevalent medical disorder on the planet (lancet

More information

Headaches in the Pediatric Emergency Dept

Headaches in the Pediatric Emergency Dept Headaches in Children February 23, 2011 Jinny Tavee, MD Associate Professor Neuromuscular Center Cleveland Clinic Foundation Cleveland, OH 1 Headaches in the Pediatric Emergency Dept Burton Gutierrez Kan

More information

Disclosures. Objectives 6/2/2017

Disclosures. Objectives 6/2/2017 Classification: Migraine and Trigeminal Autonomic Cephalalgias Lauren Doyle Strauss, DO, FAHS Assistant Professor, Child Neurology Assistant Director, Child Neurology Residency @StraussHeadache No disclosures

More information

Clinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.

Clinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache. OVERVIEW Refractory headaches and update on novel treatment Definition of refractory headache Treatment approach Medications Neuromodulation In the pipeline Juliette Preston, MD OHSU Headache Center Refractory

More information

Headache Pain Generators

Headache Pain Generators Objectives 1. Define the major categories of headache. 2. Take a history directed at characterizing a headache pattern in an individual patient and identify the cause or triggers of the headache. 3. Understand

More information

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN Current Migraine Treatment Therapy Daniel Kassicieh, DO, FAAN Migraine a Disease Process Migraines are a chronic disease process similar to many other chronic medical conditions Migraine has a low mortality

More information

Stuart Weatherby Consultant Neurologist Derriford Hospital. Plymouth

Stuart Weatherby Consultant Neurologist Derriford Hospital. Plymouth Stuart Weatherby Consultant Neurologist Derriford Hospital. Plymouth What is chronic headache? What are the causes? Why do people get headaches anyway? Why are there different sorts of headache? A model

More information

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders Goals One-Year Prevalence of Common Headache Disorders Impact of primary headache syndromes Non pharmacologic Rx of migraine individualized to patient triggers Complementary and alternative Rx of migraine

More information

Headaches in Pregnancy Before, During, and After

Headaches in Pregnancy Before, During, and After Headaches in Pregnancy Before, During, and After Robert Kaniecki, MD Director, UPMC Headache Center Assistant Professor of Neurology University of Pittsburgh Headaches and Pregnancy Pre-pregnancy counseling

More information

July 2012 Target Population. Adult patients 18 years or older in primary care settings.

July 2012 Target Population. Adult patients 18 years or older in primary care settings. Guideline for Primary Care Management of Headache in Adults July 2012 Target Population Adult patients 18 years or older in primary care settings. Exclusions: This guideline does not provide recommendations

More information

10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY

10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES JENNIFER SHIN, PHARMD PGY2 AMBULATORY CARE PHARMACY RESIDENT COMMUNITYCARE HEALTH CENTERS PHARMACOTHERAPY ROUNDS OCTOBER 20, 2017

More information

ADVANCES IN MIGRAINE MANAGEMENT

ADVANCES IN MIGRAINE MANAGEMENT ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades

More information

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am

More information

6/2/2017. Objectives. Statement of Problem: Migraine Headaches Are Common. Chronic Headache In Pediatrics, Botox and Beyond

6/2/2017. Objectives. Statement of Problem: Migraine Headaches Are Common. Chronic Headache In Pediatrics, Botox and Beyond Chronic Headache In Pediatrics, Botox and Beyond Ken Mack MD PhD Mayo Clinic 2015 MFMER slide-1 Objectives Understand pediatric chronic headache presentations Review evidence for the treatment of chronic

More information

Headache. Luke Bennetto Consultant Neurologist Engineers House 13 th September 2016

Headache. Luke Bennetto Consultant Neurologist Engineers House 13 th September 2016 Headache Luke Bennetto Consultant Neurologist Engineers House 13 th September 2016 Contents General thoughts Primary headache Secondary headache I want to curl up in a cave and die I want to drill a

More information

Headache. Section 1. Migraine headache. Clinical presentation

Headache. Section 1. Migraine headache. Clinical presentation Section 1 Headache Migraine headache 1 Clinical presentation It is important to recognize just how significant a problem migraine headache is. It has been estimated that migraine affects 11% of the United

More information

Classification and WHO ICD-10NA Codes

Classification and WHO ICD-10NA Codes Classification and WHO ICD-10NA Codes IHS WHO Diagnosis ICHD-II ICD-10NA [and aetiological ICD-10 code for secondary headache disorders] code code 1. [G43] Migraine 1.1 [G43.0] Migraine without aura 1.2

More information

Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital

Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital Honorarium from Current Pain and Headache Reports; Section Editor Unusual

More information

Risk Factors, Clinical Course, and Barriers to Care in Adults and Pediatrics. Rebecca R. Buttaccio, PA-C Dent Neurologic Institute

Risk Factors, Clinical Course, and Barriers to Care in Adults and Pediatrics. Rebecca R. Buttaccio, PA-C Dent Neurologic Institute Risk Factors, Clinical Course, and Barriers to Care in Adults and Pediatrics Rebecca R. Buttaccio, PA-C Dent Neurologic Institute Speaker for Avanir Disclosures Learning Objectives 1. Review the risk factors

More information

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Objectives Present patient case Review epidemiology/pathophysiology

More information

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Headache in children and adolescents Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Dept. of Psychiatry of Childhood and Adolescence Medical University of Vienna, Vienna, Austria Impact

More information

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest. Faculty Disclosure Karen L. Bremer, MD Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest. HEADACHE UPDATE Karen L. Bremer, MD November 10, 2017 karen.bremer@creighton.edu

More information

Treatments for migraine

Treatments for migraine Treatments for migraine Information for patients and carers Department of Neurology Aberdeen Royal Infirmary Contents Page About this leaflet Abortive medication for migraine Painkillers Antisickness medication

More information

Subject: CGRP Inhibitors

Subject: CGRP Inhibitors ARCHIVED (NOT ACTIVE RETIRED) Archived: 08/01/18 09-J2000-98 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 08/01/18 Next Review: ARCHIVED (NOT ACTIVE RETIRED) Subject: CGRP Inhibitors THIS

More information

Classification of headaches

Classification of headaches Classification of headaches Jasna Zidverc Trajković Headache center Headache in adults: 1-year prevalence 13.4 Kryst 35.9 Miranda 28.7 Jaillard 87.3 O Brien 63.1 Wiehe 37.3 Lavados 59.7 Schwartz 76.0 Boardman

More information

An Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California

An Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California An Overview of MOH IHS ASIAN HA MASTERS SCHOOL MARCH 24, 2013 ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California President-Elect

More information

Can I send this headache patient home? Dr Nicola Giffin Consultant Neurologist Bath, Nov 2017

Can I send this headache patient home? Dr Nicola Giffin Consultant Neurologist Bath, Nov 2017 Can I send this headache patient home? Dr Nicola Giffin Consultant Neurologist Bath, Nov 2017 SAH v benign thunderclap headaches Other pathologies not apparent on CT Severe primary headaches: management

More information

Prednisone vs. placebo in withdrawal therapy following medication overuse headache

Prednisone vs. placebo in withdrawal therapy following medication overuse headache doi:10.1111/j.1468-2982.2007.01488.x Prednisone vs. placebo in withdrawal therapy following medication overuse headache L Pageler 1,2, Z Katsarava 2, HC Diener 2 & V Limmroth 1,2 1 Department of Neurology,

More information

Zonisamide for migraine prophylaxis in refractory patients

Zonisamide for migraine prophylaxis in refractory patients Thomas Jefferson University Jefferson Digital Commons Department of Neurology Faculty Papers Department of Neurology March 2006 Zonisamide for migraine prophylaxis in refractory patients Avi Ashkenazi

More information

Lynne Kerr, MD May 2014

Lynne Kerr, MD May 2014 Lynne Kerr, MD May 2014 Headache is one of top 5 health problems in children 2 nd most common diagnosis in the peds neurology outpatient clinic 14 year old girl severe headache Headaches 1-2 times/month

More information

Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches

Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, 2016 II. Management of Refractory Headaches Case presentation 1: A case of intractable daily-persistent headache Keio University School

More information

MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache

MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache Measure Description Percentage of patients age 18 years old and older diagnosed with migraine headache whose migraine frequency is 4 migraine

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association CGRP Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests

More information

Case Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches

Case Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches Agenda Case presentation Migraine Morphology Primary and Premonitory Phase Secondary Headache Aura Headache Primer on Pain Medication Overuse Headache Case Presentation RT is a 25 year old woman with daily

More information

Original Policy Date

Original Policy Date MP 7.01.105 Occipital Nerve Stimulation Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return to Medical Policy

More information

Outpatient Headache Care Guideline

Outpatient Headache Care Guideline 1 Outpatient Care Guideline Inclusion criteria: children > 3 yrs with headaches Is urgent emergency department, neuroimaging, or Neurology consultation indicated? Referral to ED if: New severe headache

More information

Primary Care Adult Headache Management Pathway (formerly North West Headache Management Guideline for Adults) Version 1.0

Primary Care Adult Headache Management Pathway (formerly North West Headache Management Guideline for Adults) Version 1.0 Primary Care Adult Headache Management Pathway (formerly rth West Headache Management Guideline for Adults) Version 1.0 1 VERSION CONTROL Version Date Amendments made Version 1.0 October 2018 Reformatted

More information

Policy #: 411 Latest Review Date: January 2014

Policy #: 411 Latest Review Date: January 2014 Name of Policy: Occipital Nerve Stimulation Policy #: 411 Latest Review Date: January 2014 Category: Surgery Policy Grade: B Background/Definitions: As a general rule, benefits are payable under Blue Cross

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates September 2017 By Lindsay Slowiczek, PharmD Migraines are often considered to be a condition affecting younger or middle-aged patients, during which patients experience episodic,

More information

Migraine Treatment What you need to know

Migraine Treatment What you need to know Migraine Treatment What you need to know DR NICOLE LIMBERG ST ANDREWS PLACE SPRING HILL www.migrainespecialist.com.au Migraine what is it? Primary neurobiological condition Waves of reduced brain activity

More information

GENERAL APPROACH AND CLASSIFICATION OF HEADACHES

GENERAL APPROACH AND CLASSIFICATION OF HEADACHES GENERAL APPROACH AND CLASSIFICATION OF HEADACHES CLASSIFICATION Headache is one of the most common medical complaints. Most of the population will have experienced headache, and over 5% will seek medical

More information

UCNS Course A Review of ICHD-3b

UCNS Course A Review of ICHD-3b UCNS Course A Review of ICHD-3b Andrew D. Hershey, M.D., Ph.D., FAHS Endowed Chair and Director of Neurology Director, Cincinnati Children s Headache Center Professor of Neurology and Pediatrics University

More information

This policy addresses only the type B formulation rimabotulinumtoxinb marketed as Myobloc.

This policy addresses only the type B formulation rimabotulinumtoxinb marketed as Myobloc. RimabotulinumtoxinB NDC CODE(S) 10454-0710-XX Myobloc 2500 UNIT/0.5ML SOLN (SOLSTICE NEUROSCIENCES) 10454-0711-XX Myobloc 5000 UNIT/ML SOLN (SOLSTICE NEUROSCIENCES) 10454-0712-XX Myobloc 10000 UNIT/2ML

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest

More information

Treatment Of Medication. Overuse Headache

Treatment Of Medication. Overuse Headache 7 November 2012 BASH GPwSI Meeting Lecture title... Treatment Of Medication Dr... Overuse Headache Dr Marcus Lewis Dr... The National Migraine Centre International Headache Society Diagnostic criteria

More information

HEADACHE. Dr Nick Pendleton. September Headache

HEADACHE. Dr Nick Pendleton. September Headache HEADACHE Dr Nick Pendleton September 2017 Headache Tension Type Headache Cranial Nerve Examination Migraine Migraine Treatment Medication Overuse Headache Headache Red Flags Sinusitis Headache Raised ICP

More information

Proposed Project Scope. OPTIMAL USE OnabotulinumtoxinA for the Prevention of Chronic Migraine Clinical Evidence, Policies and Practice

Proposed Project Scope. OPTIMAL USE OnabotulinumtoxinA for the Prevention of Chronic Migraine Clinical Evidence, Policies and Practice Proposed Project Scope OPTIMAL USE OnabotulinumtoxinA for the Prevention of Chronic Migraine Clinical Evidence, Policies and Practice May 2018 1. BACKGROUND AND RATIONALE Migraine is a common, debilitating

More information

David W. Dodick M.D. Professor Director of Headache Medicine Department of Neurology Mayo Clinic Phoenix Arizona USA

David W. Dodick M.D. Professor Director of Headache Medicine Department of Neurology Mayo Clinic Phoenix Arizona USA Headache Masters School 2013 in Asia Sunday March 24, 2013 Procedural Medicine Workshop Onabotulinumtoxin A: Evidence, Injection Technique, and Mechanism of Action David W. Dodick M.D. Professor Director

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association CGRP Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests

More information

MIGRAINE A MYSTERY HEADACHE

MIGRAINE A MYSTERY HEADACHE MIGRAINE A MYSTERY HEADACHE The migraine is a chronic neurological disease that is characterized by moderate to severe episodes of headache that is mostly associated with other central nervous system (CNS)

More information

MEDICAL POLICY I. POLICY II. PRODUCT VARIATIONS TOP III. DESCRIPTION/BACKGROUND POLICY TITLE SPHENOPALATINE GANGLION BLOCK POLICY NUMBER MP-4.

MEDICAL POLICY I. POLICY II. PRODUCT VARIATIONS TOP III. DESCRIPTION/BACKGROUND POLICY TITLE SPHENOPALATINE GANGLION BLOCK POLICY NUMBER MP-4. Original Issue Date (Created): 2/1/2018 Most Recent Review Date (Revised): 7/5/2018 Effective Date: 9/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER

More information

Recognition and treatment of medication overuse headache

Recognition and treatment of medication overuse headache Recognition and treatment of medication overuse headache Marcus Lewis MA, MRCGP, DRCOG, DFSRH 20 Mean weekly headache index 15 10 5 Medication overuse headache is a common condition responsible for a high

More information

SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)

SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) 9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS

More information

Headache. Susan Hickenbottom MD, MS February 24, 2015

Headache. Susan Hickenbottom MD, MS February 24, 2015 Headache Susan Hickenbottom MD, MS February 24, 2015 Epidemiology One of most common complaints in primary care 90% of US population 50% at least one severe 25% recurrent disabling attacks 5% chronic daily

More information

BOTULINUM TOXIN POLICY TO INCLUDE:

BOTULINUM TOXIN POLICY TO INCLUDE: BOTULINUM TOXIN POLICY TO INCLUDE: Blepharospasm in adults, Hemi facial spasm in adults, spasmodic torticollis (cervical dystonia), focal spasticity treatment of dynamic equinus foot deformity, focal spasticity

More information

How could I be having migraine when I don't have a headache?

How could I be having migraine when I don't have a headache? Migraine Your doctor thinks you may have migraine. Classic migraine attacks start with visual symptoms (often zig-zag colored lights or flashes of light expanding to one side over 10-30 minutes) followed

More information

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD } Depomed Consultant 2014 to present } Avanir Consultant 2014 to present } Amgen

More information

Specific Objectives A. Topics to be lectured and discussed at the plenary sessions

Specific Objectives A. Topics to be lectured and discussed at the plenary sessions Specific Objectives A. Topics to be lectured and discussed at the plenary sessions 0. Introduction: Good morning ICHD-III! Let s start at the very beginning. When you read you begin with A-B-C, so when

More information

Primary Headache Disorders

Primary Headache Disorders Ravishankar, et al: Headache disorders S41 emphasize that the primary physicians should know when to get a neuroimaging in a headache patient to rule out the secondary causes of headache. Also, they should

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Patient Reported Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Patient Reported Outcome High Priority Quality ID #435: Quality of Life Assessment For Patients With Primary Headache Disorders National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Patient Reported Functional Outcomes

More information

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 5/18/17 SECTION: DRUGS LAST REVIEW DATE: 5/17/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 5/18/17 SECTION: DRUGS LAST REVIEW DATE: 5/17/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE: ALLZITAL (butalbital and acetaminophen) 25 mg/325 mg oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Subject: Aimovig (erenumab) Original Effective Date: 7/10/2018. Policy Number: MCP-320. Revision Date(s):

Subject: Aimovig (erenumab) Original Effective Date: 7/10/2018. Policy Number: MCP-320. Revision Date(s): Subject: Aimovig (erenumab) Original Effective Date: 7/10/2018 Policy Number: MCP-320 Revision Date(s): Review Date(s): MCPC Approval Date: 7/10/2018 DISCLAIMER This Molina Clinical Policy (MCP) is intended

More information

Classification of headaches

Classification of headaches Classification of headaches Primary headaches OR Idiopathic headaches Secondary headaches OR Symptomatic headaches THE HEADACHE IS ITSELF THE DISEASE NO ORGANIC LESION IN THE BEACKGROUND TREAT THE HEADACHE!

More information

25/09/2018 HEADACHE. Dr Nick Pendleton

25/09/2018 HEADACHE. Dr Nick Pendleton HEADACHE Dr Nick Pendleton September 2018 1 Small Group Work Tension Type Headache Cranial Nerve Examination Migraine Migraine Treatment Medication Overuse Headache Headache Red Flags Sinusitis Headache

More information

Medication Prior Authorization Form

Medication Prior Authorization Form (OnabotulinumtoxinA) Dysport (abobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Xeomin (incobotulinumtoxina) Policy Number: 1042 Policy History Approve Date: 12/11/2015 Revise Dates: 7/7/2016 Next Review:

More information

Preventive Effect of Greater Occipital Nerve Block on Severity and Frequency of Migraine Headache

Preventive Effect of Greater Occipital Nerve Block on Severity and Frequency of Migraine Headache Proceeding S.Z.P.G.M.I. Vol: 31(2): pp. 75-79, 2017. Preventive effect of Greater Occipital Nerve Block on Severity and Frequency of Migraine Headache Dr. Syed Mehmood Ali, Dr. Mudassar Aslam, Dr. Dawood

More information